



## **Clinical Edit Criteria Proposal**

Drug/Drug Class:	Sucralfate (Carafate) Clinical Edit					
Prepared for: Prepared by:	Missouri Medicaid Heritage Information Systems, Inc.					
New Criteria	Criteria Revision of Existing Criteria					
xecutive Su	ımmary					
Purpose:	Promote prudent prescribing of sucralfate with regards to indication and duration of use.					
Why was this Issue Selected:	Oral sucralfate is primarily indicated for short-term treatment of duodenal ulcers. In the treatment of gastrointestinal conditions, sucralfate monotherapy is not considered first line treatment. Additionally, sucralfate acute treatment doses, or use in combination with a $\rm H_2$ antagonist or proton pump inhibitors, may be continued long-term while providing no additional benefit and may also interfere with concurrent therapy.					
Program- specific information:	<ul><li>Drug</li><li>Sucralfate (Carafate)</li></ul>	<b>Claims</b> 21,087 (4/02-3/03)	<b>Expense</b> \$772,964			
Setting & Population:	Medicaid fee-for-service patients diagnosed of GI Ulceration.					
Type of		☐ Non-Preferred Agent				
Criteria:	☐ Appropriate Indications					
Data Sources:	☐ Only administrative databases	☐ Databases + P supplied	rescriber-			

## **Setting & Population**

• Drug/drug class for review: sucralfate

Age range: ≥ 19 years of age
Gender: males and females

### **Approval Criteria**

Approval Diagnoses								
Condition	Submitted ICD-9 Diagnoses/CPT Procedure Codes	Inferred Drugs	Date Range	Client Approval (Initials)				
Ulcer of Esophagus	530.2		2 years					
Gastric Ulcer	531		2 years					
Duodenal Ulcer	532		2 years					
Peptic Ulcer	533		2 years					
Gastrojejunal Ulcer	534		2 years					
Stomatitis	528		2 years					
	140 - 208	NA	2 years					
Cancer	NA	Antineopl astics	12 months					
	Presence of V22-V39 or 640-648*		320 days					
Pregnancy	Absence of V21, V24, V27, 72, 73, 59400-59430, 59510-59525, 59610-59622, 641-676 <sup>1</sup> , 763, 634-639,		320 days					

### **Denial Criteria**

- > 8 weeks of maintenance therapy (i.e., 4 gms per day).
- Greater than 4 weeks therapy in conjunction with H2-Antagonist or PPI.
- Patients with a history of stomatitis, cancer, or current pregnancy as defined above will be excluded from denial criteria evaluation.

Required Documentation						
Laboratory results: MedWatch form:		Progress notes:				

### **Disposition of Edit**

Denial: Exception Code "710" (Excessive Duration)

#### References

1. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2003.



# **Client Approval**

Please	have	an	authori	zed i	representative	execute	this	Clinical	Edit	criteria	verifying
receipt	by the	clie	ent and	that a	all elements co	ntained h	ereir	are und	dersto	od.	

Client Name:	 	
Signature:	 	
Date:		

